Captrust Financial Advisors Prothena Corp Public LTD CO Transaction History

Captrust Financial Advisors

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$47.3 - $70.6 $6,811 - $10,166	-144 Reduced 3.21%	4,338 $209,000
Q2 2023 Aug 14, 2023	SELL	$48.26 - $78.59 $3,281 - $5,344	-68 Reduced 1.49%	4,482 $306,000
Q1 2023 May 15, 2023	BUY	$46.97 - $58.27 $26,960 - $33,446	574 Added 14.44%	4,550 $220,000
Q4 2022 Feb 15, 2023	BUY	$52.05 - $65.0 $206,950 - $258,440	3,976 New	3,976 $239,000
Q2 2022 Aug 23, 2022	SELL	$22.73 - $39.98 $159 - $279	-7 Reduced 0.59%	1,177 $32,000
Q2 2022 Aug 16, 2022	SELL	$22.73 - $39.98 $3,091 - $5,437	-136 Reduced 10.3%	1,184 $32,000
Q1 2022 May 16, 2022	SELL	$30.27 - $49.22 $3,359 - $5,463	-111 Reduced 7.76%	1,320 $48,000
Q4 2021 Feb 14, 2022	SELL	$42.11 - $73.26 $24,086 - $41,904	-572 Reduced 28.56%	1,431 $71,000
Q3 2021 Nov 16, 2021	BUY	$48.2 - $78.89 $64,877 - $106,185	1,346 Added 204.87%	2,003 $143,000
Q2 2021 Aug 16, 2021	SELL	$21.63 - $57.65 $584 - $1,556	-27 Reduced 3.95%	657 $34,000
Q1 2021 May 17, 2021	BUY	$11.0 - $28.24 $7,315 - $18,779	665 Added 3500.0%	684 $17,000
Q4 2020 Feb 16, 2021	BUY	$10.12 - $13.94 $192 - $264	19 New	19 $0

198

44.5M

601K

259K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $701M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.